Abstract
68Ga-DOTATATE uptake in mesenchymal tumors causing hypophosphatemic osteomalacia has been recently described. Herein, we present a case of 68Ga-DOTATATE uptake in an intramastoid phosphaturic mesenchymal tumor that had not been depicted in previous 99mTc-Sestamibi and 18F-FDG scans. The lesion was surgically removed and the phosphorus level increased to the normal range.
This is a preview of subscription content, log in via an institution to check access.
References
Jan de Beur SM. Tumor-induced osteomalacia. JAMA. 2005;294:1260–7.
Weidner N, Bar RS, Weiss D, Strottmann MP. Neoplastic pathology of oncogenic osteomalacia/rickets. Cancer. 1985;55:1691–705.
Reubi JC, Waser B, Laissue JA, Gebbers JO. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. Cancer Res. 1996;56:1922–31.
Rhee Y, Lee JD, Shin KH, Lee HC, Huh KB. Lim SK Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy. Clin Endocrinol. 2001;54:551–4.
Nguyen BD, Wang EA. Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clin Nucl Med. 1999;24:130–1.
Zhang J, Zhu Z, Zhong D, Dang Y, Xing H, Du Y, et al. 68Ga DOTATATE PET/CT is an accurate imaging modality in the detection of culprit tumors causing osteomalacia. Clin Nucl Med. 2015;40:642–6.
Clifton-Bligh RJ, Hofman MS, Duncan E, IeW S, Darnell D, Clarkson A, et al. Improving diagnosis of tumor-induced osteomalacia with gallium-68 DOTATATE PET/CT. J Clin Endocrinol Metab. 2013;98:687–94.
Agrawal K, Bhadada S, Mittal BR, Shukla J, Sood A, Bhattacharya A, et al. Comparison of 18F-FDG and 68Ga DOTATATE PET/CT in localization of tumor causing oncogenic osteomalacia. Clin Nucl Med. 2015;40:e6–e10.
Paquet M, Gauthé M, Yin JZ, Nataf V, Bélissant O, Orcel P, et al. Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET/CT for detecting osteomalacia-associated tumours. Eur J Nucl Med Mol Imaging. 2018;45:1710–20.
Houang M, Clarkson A, Sioson L, Elston MS, Clifton-Bligh RJ, Dray M, et al. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Human Pathol. 2013;44:2711–8.
Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28:1–30.
Weidner N, Cruz DS. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer. 1987;59:1442–54.
Acknowledgments
The authors are grateful to Drs. Vitor Gabriel Ribeiro Grossi and Eloiza Wilma Poma Gonzales for providing the histological images.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Carlo Scognamiglio Renner Araujo, Luciana Parente Costa Seguro, Paulo Schiavom Duarte, Carlos Alberto Buchpiguel, and Rosa Maria Rodrigues Pereira declare that they have no conflict of interest.
Ethical Statement
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed Consent
The institutional review board of our institute approved this study, and the requirement to obtain informed consent was waived.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Araujo, C.S.R., Seguro, L.P.C., Duarte, P.S. et al. Intramastoid Phosphaturic Mesenchymal Tumor Causing Hypophosphatemic Osteomalacia Detected on 68Ga-DOTATATE PET/CT But Not on 99mTc-Sestamibi and 18F-FDG Scans. Nucl Med Mol Imaging 53, 436–441 (2019). https://doi.org/10.1007/s13139-019-00616-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13139-019-00616-8